Condition

Neuroendocrine Tumors clinical trials and research

• 61Clinical trials
• 25NIH research projects
• 18Countries

Newest Neuroendocrine Tumors clinical trials

All recruiting trials (61)

• New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans

  A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.

  Recruiting at 2 sites Phase 2 Peking University First Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07733024

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors

  This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.

  Recruiting at 2 sites Phase 2 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07404176

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors

  This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07366658

• Cabozantinib for adults with previously treated neuroendocrine tumors

  This study will see how cabozantinib works and how safe it is for adults with neuroendocrine tumors that have continued to grow after prior systemic treatment.

  Recruiting at 23 sites Ipsen · Graz and 40 other locations · NCT07314164

• Surufatinib for adults with advanced neuroendocrine neoplasms in routine care

  This study will see if daily oral surufatinib, given alone or with other treatments, helps adults with advanced neuroendocrine tumors when used in regular clinical practice.

  Recruiting at 4 sites Phase 4 Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07272512

• RYZ401 for solid tumors that express somatostatin receptors

  This trial will try RYZ401, a targeted radiotherapy, in adults with neuroendocrine or other solid tumors that show somatostatin receptors to find a safe dose and see if it shrinks tumors.

  Recruiting at 15 sites Phase 1 RayzeBio, Inc. · Phoenix, Arizona and 14 other locations · NCT07165132

• Guarana for reducing fatigue in people with neuroendocrine or gynecologic cancers

  We will test whether taking guarana can help reduce fatigue in adults with neuroendocrine tumors or gynecologic cancers.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT07151391

• Using a new molecular probe for early diagnosis of tumors

  This study is testing a new imaging tool to see if it can help doctors find different types of tumors earlier in patients aged 18 to 75 who already have confirmed tumor lesions.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT06937112

• Dual-nuclide PET/CT imaging to test simultaneous tracer separation in cancer patients and healthy volunteers

  This study tests a simultaneous dual-tracer PET/CT imaging method in prostate cancer, neuroendocrine tumors, glioma, lung cancer patients, and healthy volunteers to see if it can accurately separate and measure two tracers in humans.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT06914427

• Social needs screening and connection program for Metro Detroit cancer survivors

  This project will test whether cancer survivors in Metro Detroit can complete a social needs screening and be connected to community resources for food and digital access.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT06908629

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Investigating the impact of somatostatin analogues on tumor dose during radionuclide therapy

  This study is testing if stopping or continuing long-acting somatostatin treatment affects how well radionuclide therapy works for adults with neuroendocrine tumors.

  Recruiting Phase 2/3 The Netherlands Cancer Institute · Amsterdam · NCT06855095

• Testing a new drug for advanced solid tumors that express c-Kit

  This study is testing a new drug for people with advanced solid tumors that have a specific marker called c-Kit to see if it is safe and how well it works.

  Recruiting at 4 sites Phase 1 Novelty Nobility, Inc. · Ann Arbor, Michigan and 4 other locations · NCT06805825

• PET/CT with zirconium‑labelled girentuximab to image CAIX in liver and gastro‑entero‑pancreatic neuroendocrine tumors

  This will test whether a PET/CT scan using zirconium‑labelled girentuximab can find CAIX‑expressing hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and gastro‑entero‑pancreatic neuroendocrine tumors in adults.

  Recruiting Nantes University Hospital · Nantes and 1 other locations · NCT06735560

• Evaluating BL-M14D1 for advanced small cell lung cancer and other solid tumors

  This study is testing a new treatment called BL-M14D1 to see if it can help people with advanced small cell lung cancer and other solid tumors who have run out of other treatment options.

  Recruiting Phase 1 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06505824

• Comparing two doses of Everolimus for treating neuroendocrine tumors

  This study is testing whether a lower dose of Everolimus can effectively treat patients with advanced neuroendocrine tumors while causing fewer side effects compared to a higher dose.

  Recruiting at 2 sites Phase 2 AC Camargo Cancer Center · São Paulo, São Paulo and 1 other locations · NCT06472388

• Using a new imaging agent to detect neuroendocrine tumors

  This study is testing a new imaging agent to see if it can better detect neuroendocrine tumors in patients compared to the current standard method.

  Recruiting Phase 1/2 University Hospital, Basel, Switzerland · Basel, Canton of Basel-City · NCT06455358

• Evaluating HPG80 for Diagnosing Neuroendocrine Tumors in MEN1 Patients

  This study is testing if a blood marker called HPG80 can help doctors diagnose neuroendocrine tumors in patients with a genetic condition called MEN1.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT06430021

• Customized Lutetium-177 treatment for neuroendocrine tumors

  This study is testing if a personalized dose of Lutetium-177 can improve treatment results for adults with hard-to-treat neuroendocrine tumors compared to standard treatment.

  Recruiting Phase 2 University of Iowa · Iowa City, Iowa · NCT06395402

• Examining factors affecting treatment response in gastroenteropancreatic neuroendocrine tumors

  This study looks at how different factors related to tumors and patients affect how well treatments work for people with gastroenteropancreatic neuroendocrine tumors.

  Recruiting IRCCS San Raffaele · Milan · NCT06356467

• Stopping somatostatin analogues after targeted radiotherapy for neuroendocrine tumors

  This study is testing whether stopping or continuing somatostatin analogues after starting a specific radiation therapy can help people with certain neuroendocrine tumors live longer without their cancer getting worse.

  Recruiting at 17 sites Phase 2 Australasian Gastro-Intestinal Trials Group · Sydney, New South Wales and 16 other locations · NCT06345079

• Registry of images and videos from endoscopic procedures for pancreatic diseases

  This study is collecting images and videos from endoscopic procedures on patients with pancreatic diseases to help improve how these conditions are understood and treated.

  Recruiting IRCCS San Raffaele · Milan · NCT06344507

• Improving care for Black patients with gastrointestinal cancer

  This study is trying to improve cancer care for Black patients with gastrointestinal cancers by ensuring they get the right tests and treatments while helping us understand the challenges they face.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06263088

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Treatment for neuroendocrine tumors using 177Lu-DOTATOC

  This study is testing a new treatment called 177Lu-DOTATOC to see if it can help patients with certain types of neuroendocrine tumors when other treatments aren't working.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Cesena, Forlì-Cesena and 1 other locations · NCT06045260

• Testing ADCT-701 for treating neuroendocrine tumors and carcinomas

  This study is testing a new drug called ADCT-701 to see if it can safely help adults with neuroendocrine tumors and certain types of cancer.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06041516

• Combining Surufatinib with Temozolomide and S-1 for treating advanced neuroendocrine tumors

  This study is testing a new combination of three medications to see if it can help people with advanced neuroendocrine tumors who haven't had treatment before.

  Recruiting Phase 1/2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06038461

• Evaluating markers and imaging for predicting outcomes in pituitary tumors

  This study is trying to find out if certain blood tests and scans can help predict how aggressive pituitary tumors will be and how well patients will do over time.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06015802

• Comparing radiotherapy and everolimus for treating neuroendocrine tumors in the lung and thymus

  This study is testing whether a new treatment called 177Lu-edotreotide is better than everolimus for helping people with neuroendocrine tumors in the lung and thymus live longer without their cancer getting worse.

  Recruiting at 26 sites Phase 3 Grupo Espanol de Tumores Neuroendocrinos · Edegem, Edegem and 26 other locations · NCT05918302

• Combining olaparib with PRRT for advanced gastroenteropancreatic neuroendocrine tumors

  This trial will test whether giving the oral PARP blocker olaparib together with PRRT helps adults with advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors that progressed after prior PRRT.

  Recruiting Phase 1 Erasmus Medical Center · Rotterdam, South Holland · NCT05870423

• Long-term outcomes of endoscopic procedures for upper gastrointestinal cancers

  This study looks at how well certain endoscopic procedures work for treating larger upper gastrointestinal cancers and what the long-term results are for patients.

  Recruiting Western Sydney Local Health District · Sydney, New South Wales · NCT05804331

• Combining lenvatinib and pembrolizumab for treating well-differentiated G3 neuroendocrine tumors

  This study is testing if combining two medications, lenvatinib and pembrolizumab, can help people with well-differentiated grade 3 neuroendocrine tumors feel better and improve their treatment outcomes.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT05746208

• Using metronomic temozolomide for patients with advanced neuroendocrine tumors who are unfit for standard treatments

  This study is testing if a continuous low-dose chemotherapy called metronomic temozolomide can help people with advanced neuroendocrine tumors who can't tolerate standard treatments feel better and live longer.

  Recruiting Phase 2 European Institute of Oncology · Milan · NCT05554003

• Comparing in-person and remote monitoring for cancer follow-up

  This study is testing whether patients with rare tumors follow their post-treatment care plans better with in-person visits from a doctor or remote check-ins with a nurse.

  Recruiting Phase 2 Centre Oscar Lambret · Amiens and 2 other locations · NCT05500391

• Monitoring targeted therapy drugs in patients with advanced digestive cancers

  This study is testing how to best monitor and adjust the doses of targeted therapy drugs for people with advanced digestive cancers to make sure they are safe and effective.

  Recruiting at 19 sites Unicancer · Amiens and 28 other locations · NCT05443087

• Personalized treatment for neuroendocrine tumors using targeted radiation therapy

  This study is testing whether a personalized type of radiation therapy can work better than a standard version for people with advanced neuroendocrine tumors.

  Recruiting at 4 sites Phase 3 Lund University Hospital · Gothenburg and 3 other locations · NCT05387603

• Alternative dosing schedule for cabozantinib in advanced kidney and neuroendocrine tumors

  This study is testing a new way to give cabozantinib to see if it helps people with advanced kidney cancer and neuroendocrine tumors feel better and stay safe while being treated.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05263050

• Study of Neuroendocrine Neoplasms and Adrenocortical Carcinoma

  This study is trying to learn more about how neuroendocrine tumors and adrenocortical carcinoma behave over time by collecting samples and information from people who have these rare cancers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05237934

• Combining ASTX727 with Lutathera for Neuroendocrine Tumors

  This study is testing whether taking ASTX727 for five days before Lutathera treatment can help people with metastatic neuroendocrine tumors by looking at changes in a specific receptor.

  Recruiting Phase 1 Imperial College London · London, London, City of · NCT05178693

• Total-body PET with FDA-approved Tracers Beyond 18F-FDG

  This small, non-randomized study tests how well the total-body PET/CT scanner can image prostate cancer, breast cancer, and neuroendocrine tumors using three approved tracers to see if images are clearer or more informative.

  Recruiting University of California, Davis · Sacramento, California · NCT05160480

• Combining a PARP inhibitor with targeted radiation therapy for neuroendocrine tumors

  This study is testing if combining a new cancer drug with targeted radiation therapy can safely help people with advanced pancreatic or midgut neuroendocrine tumors.

  Recruiting Phase 1 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria · NCT05053854

• Combining Atezolizumab and Tivozanib for Treating Certain Cancer Types

  This study is testing a new combination of two cancer drugs, Atezolizumab and Tivozanib, to see if they can help people with tough-to-treat cancers like bile duct, gallbladder, breast, and neuroendocrine tumors.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT05000294

• Retreatment with Lutathera® for patients with progressing intestinal neuroendocrine tumors

  This study is testing if giving more doses of Lutathera® to patients with progressing intestinal neuroendocrine tumors can help them live longer without their cancer getting worse, compared to just keeping an eye on their condition.

  Recruiting at 27 sites Phase 2 Institut du Cancer de Montpellier - Val d'Aurelle · Angers and 27 other locations · NCT04954820

• Pooling clinical experiences of patients treated with Lutetium-177 in Spain

  This study looks at how well Lutetium-177 works and how safe it is for patients with certain types of tumors in Spain by collecting information from their medical records.

  Recruiting at 11 sites Sociedad Española de Medicina Nuclear e Imagen Molecular · Santiago de Compostela, A Coruña and 19 other locations · NCT04949282

• Imaging of suspected somatostatin receptor positive tumors using 68Ga-HA-DOTATATE

  This study is testing a new type of imaging called 68Ga-HA-DOTATATE PET/CT to see if it can better help people with suspected somatostatin receptor positive tumors compared to regular CT and MRI scans.

  Recruiting Phase 2 University of Alberta · Edmonton, Alberta · NCT04888481

• Optimizing PET Imaging with 18F-DOPA for Various Conditions

  This study is testing if a special imaging technique using 18F-DOPA can help doctors see and understand conditions like congenital hyperinsulinism, neuroblastoma, neuroendocrine tumors, Parkinson's disease, and Lewy body dementia better in both kids and adults.

  Recruiting Phase 3 University of Alberta · Edmonton, Alberta · NCT04706910

• Exploring new biomarkers for diagnosing and treating neuroendocrine tumors

  This study is testing new ways to diagnose and treat neuroendocrine tumors by looking at blood samples to see if they can provide better information about the cancer.

  Recruiting University of Roma La Sapienza · Rome, Italy · NCT04464122

• Combination therapy for Grade 2 liver-dominant neuroendocrine tumors

  This study is testing a new combination treatment of two drugs followed by a special radiation therapy to see if it helps people with Grade 2 liver-dominant neuroendocrine tumors live longer without their cancer getting worse.

  Recruiting Phase 2 Abramson Cancer Center at Penn Medicine · La Jolla, California and 4 other locations · NCT04339036

• Vaccination with Dendritic Cells for Patients with Resected Stage IV Rare Cancers

  This study is testing a new vaccine made from patients' own immune cells to see if it can help people who have had rare stage IV cancers feel better and stay healthy after surgery.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC · NCT04166006

• Gene modified immune cells for treating advanced melanoma and metastatic solid tumors

  This study is testing if modified immune cells can safely target and attack advanced melanoma and other solid tumors in patients after they receive chemotherapy.

  Recruiting at 3 sites Phase 1 Stanford University · Duarte, California and 2 other locations · NCT04119024

• Database for patients treated with metabolic radiotherapy

  This study is creating a database to collect information and samples from patients with thyroid, prostate, and neuroendocrine tumors who are receiving targeted radiation therapy, to see how it works and improve treatment.

  Recruiting at 3 sites Institut du Cancer de Montpellier - Val d'Aurelle · Bordeaux, Aquitaine and 3 other locations · NCT04104529

• Peptide receptor radionuclide therapy for gastroenteropancreatic neuroendocrine tumors

  This study will collect information to see how well peptide receptor radionuclide therapy (PRRT) works and how safe it is for adults with gastroenteropancreatic neuroendocrine tumors.

  Recruiting Methodist Health System · Dallas, Texas and 1 other locations · NCT04090034

• Combining Lutathera and Olaparib for Inoperable Neuroendocrine Tumors

  This study is testing if combining Lutathera and Olaparib can safely shrink tumors in adults with inoperable gastroenteropancreatic neuroendocrine tumors.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04086485

• Understanding and managing pancreatic tumors in patients with Von Hippel-Lindau disease

  This study is testing how pancreatic tumors behave in people with Von Hippel-Lindau disease to improve detection and management of these tumors.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04074135

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Using genetically modified T-cells to target cancer mutations in patients with metastatic cancer

  This study is testing a new treatment that uses specially modified immune cells from cancer patients to see if they can better target and shrink tumors in people with advanced cancer who haven't responded to regular treatments.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03412877

• Treatment for inoperable pheochromocytoma and paraganglioma using Lu-177-DOTATATE

  This study is testing if a new treatment called Lu-177-DOTATATE can help people with inoperable pheochromocytoma and paraganglioma by delaying the return of their tumors.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03206060

• Combining tirapazamine with embolization for liver cancer treatment

  This study is testing a new way to treat liver cancer by combining a drug called tirapazamine with a procedure called embolization to see how well it works and how much of the drug can be safely given to patients.

  Recruiting at 2 sites Phase 1/2 Teclison Ltd. · Palo Alto, California and 1 other locations · NCT02174549

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

NIH-funded research (25)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors

  A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11473762

• Enteric glial cell reprogramming and MENIN loss in dpNETs

  A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.

  NIH research University of Arizona · Tucson, United States · NIH-11447747

• Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy

  Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.

  NIH research University of Iowa · Iowa City, United States · NIH-11401208

• Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors

  This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.

  NIH research Research Inst Nationwide Children's Hosp · Columbus, United States · NIH-11362251

• SSTR2 imaging to guide pituitary tumor radiotherapy and planning

  This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11305252

• Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors

  A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11293502

• Receptor-targeted fluorescent guidance for pancreatic neuroendocrine tumor surgery

  A new fluorescent dye that sticks to pancreatic neuroendocrine tumors is being developed to help surgeons see and remove tumors more clearly during surgery.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11289293

• Targeting Angiopoietin‑2/Tie2 to limit liver spread of pancreatic neuroendocrine tumors

  The team is looking at whether blocking a blood‑vessel protein called Angiopoietin‑2 can reduce liver spread in people with pancreatic neuroendocrine tumors.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11211625

• Understanding and Stopping Liver Spread of Pancreatic Neuroendocrine Tumors

  This work explores how a protein called Angiopoietin-2 helps pancreatic neuroendocrine tumors spread to the liver and how blocking it might improve treatments.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11123898

• Improving Alpha-Emitter Therapy for Neuroendocrine Tumors and Protecting Kidneys

  This project looks for better ways to treat neuroendocrine tumors with a special type of radiation therapy, while also keeping kidneys safe.

  NIH research Research Inst Nationwide Children's Hosp · Columbus, United States · NIH-11115687

• Investigating a specific receptor in pituitary tumors to improve treatment planning.

  This study is looking at a common type of brain tumor called pituitary neuroendocrine tumors to see how a specific receptor can help doctors better understand the disease after surgery, with the goal of improving radiation therapy for patients who still have tumor left.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11115111

• Investigating how RABL6A and PP2A affect neuroendocrine tumors

  This study is looking at how certain proteins affect the growth of pancreatic neuroendocrine tumors, with the hope of finding new treatments that could help patients with these tough-to-treat cancers.

  NIH research University of Iowa · Iowa City, United States · NIH-11072006

• Using cell and gene therapy to treat neuroendocrine tumors

  This study is testing new treatments using donor cells to help fight rare neuroendocrine tumors, aiming to see how safe and effective these therapies are for patients who don’t have many options right now.

  NIH research Expression Therapeutics · Tucker, United States · NIH-11066857

• Understanding immune interactions in neuroendocrine tumors for better treatment options

  This study is looking at how immune cells interact with neuroendocrine tumors to find new ways to predict outcomes and improve treatments, which could help patients get better care based on the results.

  NIH research Boston Medical Center · Boston, United States · NIH-11004262

• Understanding how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors

  This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it hopes to find new ways to help patients with this type of cancer live longer and healthier lives.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10977511

• Improving targeted therapy for neuroendocrine tumors while protecting kidney health

  This study is looking at a new treatment for neuroendocrine tumors that uses special targeted therapy to help shrink tumors while protecting your kidneys, so you can get a safer and more effective plan tailored just for you.

  NIH research Research Inst Nationwide Children's Hosp · Columbus, United States · NIH-10942787

• Understanding how Notch2 affects pancreatic neuroendocrine tumors

  This study is looking at how a protein called Notch2 affects pancreatic neuroendocrine tumors, which are tricky cancers, to help doctors understand how these tumors grow and behave, with the goal of finding better ways to treat patients like you.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10924006

• Improving surgery for pancreatic neuroendocrine tumors using fluorescent agents

  This study is testing a new dye that helps surgeons see pancreatic tumors better during surgery, making it easier to remove them completely and improve recovery for patients with pancreatic neuroendocrine tumors.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-10909275

• Understanding pancreatic neuroendocrine tumors through protein analysis

  This study is looking at pancreatic neuroendocrine tumors to find out more about their different types by examining the proteins in the tumors, which could help doctors better understand how to treat patients based on their risk of spreading the cancer.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-10907222

• Improving treatment for neuroendocrine tumors using targeted therapy

  This study is looking at a new way to make treatment more effective for patients with gastroenteropancreatic neuroendocrine tumors by using a short course of chemotherapy to help their tumors respond better to a special therapy called PRRT, with the goal of improving results and reducing side effects.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-10880286

• Investigating how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors

  This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it aims to find out if blocking this protein can help slow down tumor growth and improve survival for patients with this type of cancer.

  NIH research Columbia University Health Sciences · New York, United States · NIH-10867490

• Targeted therapy using alpha particles for neuroendocrine tumors

  This study is testing a new treatment for people with advanced neuroendocrine tumors that uses a special type of radiation to help shrink tumors more effectively than current options, and it aims to create a personalized approach based on imaging to ensure safety and effectiveness.

  NIH research University of Iowa · Iowa City, United States · NIH-10850995

• A new treatment for pancreatic neuroendocrine tumors

  This study is exploring a new treatment for advanced pancreatic neuroendocrine tumors that aren't responding to current therapies, aiming to find better ways to help patients by understanding how cancer cells resist treatment.

  NIH research Wayne State University · Detroit, United States · NIH-10814877

• Exploring the role of the MAX gene in small cell lung cancer and other neuroendocrine tumors

  This study is looking at how a gene called MAX helps prevent small cell lung cancer and other similar tumors from growing, and it hopes to find new ways to treat these cancers by understanding what happens when this gene is missing.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-10811720

• A new imaging system to identify tumors in the pancreas and digestive system.

  This study is working on a new computer system that uses advanced imaging technology to help doctors find and measure gastroenteropancreatic neuroendocrine tumors more accurately, so patients can get better treatment options and care.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-10740578

Related topics

Quick answers

How many Neuroendocrine Tumors clinical trials are recruiting right now?

61, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in United States (24 trials), China (8 trials), France (7 trials), Italy (7 trials), Australia (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 11, Phase 1/2: 5, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →